Literature DB >> 7905033

Validation of the 16-item Negative Symptom Assessment.

B N Axelrod1, R S Goldman, L D Alphs.   

Abstract

The dimensional structure of the 16-item Negative Symptom Assessment (NSA-16) was validated in a sample of 223 unmedicated schizophrenic inpatients and cross-validated on an independent sample of 276 patients with schizophrenia. Using a confirmatory factor analytic procedure, a five factor model was found to best characterize the structure of this rating instrument. These factors include: Communication, Emotion/Affect, Social Involvement, Motivation, and Retardation. The latent structure of the NSA-16 is similar to the larger instrument from which it was derived. The findings provide support for a multidimensional model of negative symptoms in schizophrenia and offer a useful measure for their assessment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7905033     DOI: 10.1016/0022-3956(93)90036-2

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  31 in total

1.  The brief negative symptom scale: psychometric properties.

Authors:  Brian Kirkpatrick; Gregory P Strauss; Linh Nguyen; Bernard A Fischer; David G Daniel; Angel Cienfuegos; Stephen R Marder
Journal:  Schizophr Bull       Date:  2010-06-17       Impact factor: 9.306

2.  Placebo Response and Practice Effects in Schizophrenia Cognition Trials.

Authors:  Richard S E Keefe; Vicki G Davis; Philip D Harvey; Alexandra S Atkins; George M Haig; Owen Hagino; Stephen Marder; Dana C Hilt; Daniel Umbricht
Journal:  JAMA Psychiatry       Date:  2017-08-01       Impact factor: 21.596

3.  An industry perspective on the NIMH consensus statement on negative symptoms.

Authors:  Larry Alphs
Journal:  Schizophr Bull       Date:  2006-02-09       Impact factor: 9.306

4.  A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia.

Authors:  Dawn I Velligan; David Roberts; Jim Mintz; Natalie Maples; Xueying Li; Elisa Medellin; Matt Brown
Journal:  Schizophr Res       Date:  2015-05-01       Impact factor: 4.939

5.  Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia.

Authors:  Larry Alphs; Robert Morlock; Cheryl Coon; Pilar Cazorla; Armin Szegedi; John Panagides
Journal:  Int J Methods Psychiatr Res       Date:  2011-06       Impact factor: 4.035

6.  Methodological issues in negative symptom trials.

Authors:  Stephen R Marder; David G Daniel; Larry Alphs; A George Awad; Richard S E Keefe
Journal:  Schizophr Bull       Date:  2011-01-26       Impact factor: 9.306

Review 7.  Psychometric evaluation of the negative syndrome of schizophrenia.

Authors:  Maria Paz Garcia-Portilla; Leticia Garcia-Alvarez; Pilar A Saiz; Susana Al-Halabi; Maria Teresa Bobes-Bascaran; Maria Teresa Bascaran; José Muñiz; Julio Bobes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 5.270

8.  Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms.

Authors:  L Felice Reddy; William P Horan; Deanna M Barch; Robert W Buchanan; Eduardo Dunayevich; James M Gold; Naomi Lyons; Stephen R Marder; Michael T Treadway; Jonathan K Wynn; Jared W Young; Michael F Green
Journal:  Schizophr Bull       Date:  2015-07-03       Impact factor: 9.306

9.  The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.

Authors:  Ann M Kring; Raquel E Gur; Jack J Blanchard; William P Horan; Steven P Reise
Journal:  Am J Psychiatry       Date:  2013-02       Impact factor: 18.112

10.  Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale.

Authors:  Gregory P Strauss; William R Keller; Robert W Buchanan; James M Gold; Bernard A Fischer; Robert P McMahon; Lauren T Catalano; Adam J Culbreth; William T Carpenter; Brian Kirkpatrick
Journal:  Schizophr Res       Date:  2012-11-03       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.